SelectQuote Suffers Stock Drop Following DOJ Complaint Over Illegal Rebates

Summary

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of SelectQuote, Inc. (SLQT) due to a complaint by the U.S. Department of Justice regarding illegal kickbacks related to Medicare Advantage plans. The investigation follows a 19.24% drop in SelectQuote’s stock on May 1, 2025, to $2.56 per share after news of the lawsuit. Investors are encouraged to assist the investigation.Acceswire

Impact Analysis

SelectQuote is facing a significant litigation event due to allegations by the DOJ involving illegal kickbacks for Medicare Advantage plan enrollments to Humana and other insurers from 2016 to at least 2021.Acceswire+ 2 This litigation event is categorized under Regulatory or Litigation Events.

First-Order Effects:

• Direct Impacts: The lawsuit and subsequent investigation have led to a sharp decline in SelectQuote’s stock price by 19.24%, reflecting immediate investor concerns regarding legal liabilities and potential financial penalties.GlobeNewswire
• Risks: Legal scrutiny could lead to substantial fines, reputational damage, and operational disruptions, affecting investor confidence and future business prospects. SelectQuote disputes the DOJ’s allegations, but the litigation could be prolonged and costly.Reuters

Second-Order Effects:

• Industry Impact: This event could prompt increased regulatory scrutiny across the insurance brokerage industry, particularly around practices involving Medicare Advantage plans. Peer companies may face similar investigations or be prompted to review their compliance measures.

Investment Opportunities:

• Options strategies such as put options could be considered by investors anticipating further declines in stock value. Conversely, if SelectQuote successfully defends against the allegations, there may be opportunities for stock price recovery, warranting strategic long-term positions.

Overall, this event introduces significant risks for SelectQuote, primarily in the form of legal and reputational challenges, but it also presents a strategic moment for investors to evaluate the company’s ability to navigate regulatory hurdles and its long-term viability in the health insurance brokerage sector.Motley Fool+ 2